Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 43Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Cyclophosphamide 2toripalimab 1pembrolizumab 1fludarabine 1apatinib 1TP protocol 1Surgical Procedures, Operative 1Radiation 1Heavy Ion Radiotherapy 1Drug Therapy 1Doxorubicin 1Cisplatin 1Carboplatin 1AP 1903 reagent 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thymic epithelial tumor × apatinib × Clear all
NCT06200233 2024-04-09

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Samsung Medical Center

Phase 2 Not yet recruiting
40 enrolled

Thymic epithelial tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡